NCT03714568View on ClinicalTrials.gov

Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 11, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Pharmacokinetic
Interventions
DRUG

TQ-A3326

TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）

DRUG

placebo

Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)

Trial Locations (1)

410015

RECRUITING

The Third Hospital of Changsha, Changsha

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY